The role of histone methyltransferase EZH2 in myelodysplastic syndromes

References

• Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 24(2), 317–330 (2010).
   PubMed Web of Science ®Google Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv. Genet. 70, 27–56 (2010).
   PubMed Web of Science ®Google Scholar
• Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6(11), 846–856 (2006).
   PubMed Web of Science ®Google Scholar
• Rajasekhar VK, Begemann M. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25(10), 2498–2510 (2007).
   PubMed Web of Science ®Google Scholar
• Weinhofer I, Hehenberger E, Roszak P, Hennig L, Kohler C. H3K27me3 profiling of the endosperm implies exclusion of polycomb group protein targeting by DNA methylation. PLoS Genet. 6(10), e1001152 (2010).
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871–874 (2006).
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39(2), 232–236 (2007).
   PubMed Web of Science ®Google Scholar
• Levine SS, King IF, Kingston RE. Division of labor in polycomb group repression. Trends Biochem. Sci. 29(9), 478–485 (2004).
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298(5595), 1039–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Kirmizis A, Bartley SM, Kuzmichev A et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18(13), 1592–1605 (2004).
   PubMed Web of Science ®Google Scholar
• Iwama A, Oguro H, Negishi M, Kato Y, Nakauchia H. Epigenetic regulation of hematopoietic stem cell self-renewal by polycomb group genes. Int. J. Hematol. 81(4), 294–300 (2005).
   PubMed Web of Science ®Google Scholar
• Kamminga LM, Bystrykh LV, de Boer A et al. The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107(5), 2170–2179 (2006).
   PubMed Web of Science ®Google Scholar
• Majewski IJ, Blewitt ME, de Graaf CA et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 6(4), e93 (2008).
   PubMed Web of Science ®Google Scholar
• Fiskus W, Pranpat M, Balasis M et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther. 5(12), 3096–3104 (2006).
   PubMed Web of Science ®Google Scholar
• Villa R, Pasini D, Gutierrez A et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11(6), 513–525 (2007).
   PubMed Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665–667 (2010).
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8), 722–726 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52–57 (2007).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223–232 (2009).
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Puppe J, Drost R, Liu X et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 11(4), R63 (2009).
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Sreekumar A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13), 2733–2743 (2009).
   PubMed Web of Science ®Google Scholar
• Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol. Endocrinol. 19(3), 563–573 (2005).
   PubMed Web of Science ®Google Scholar
• Margueron R, Justin N, Ohno K et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461(7265), 762–767 (2009).
   PubMed Web of Science ®Google Scholar
• Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED–EZH2 complex. Mol. Cell 15(1), 57–67 (2004).
   PubMed Web of Science ®Google Scholar
• Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol. Cell Biol. 28(8), 2718–2731 (2008).
   PubMed Web of Science ®Google Scholar
• Landeira D, Sauer S, Poot R et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA polymerase II to developmental regulators. Nat. Cell Biol. 12(6), 618–624 (2010).
   PubMed Web of Science ®Google Scholar
• Peng JC, Valouev A, Swigut T et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139(7), 1290–1302 (2009).
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40(6), 741–750 (2008).
   PubMed Web of Science ®Google Scholar
• Gal-Yam EN, Egger G, Iniguez L et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl Acad. Sci. USA 105(35), 12979–12984 (2008).
   PubMed Web of Science ®Google Scholar
• McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res. 67(11), 5097–5102 (2007).
   PubMed Web of Science ®Google Scholar
• van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 23(4), 474–478 (1999).
   PubMed Web of Science ®Google Scholar
• Fan T, Jiang S, Chung N et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol. Cancer Res. 9(4), 418–429 (2011).
   PubMed Web of Science ®Google Scholar
• Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein. Genes Dev. 16(22), 2893–2905 (2002).
   PubMed Web of Science ®Google Scholar
• Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647(12), 21–29 (2008).
   PubMed Web of Science ®Google Scholar
• Plath K, Fang J, Mlynarczyk-Evans SK et al. Role of histone H3 lysine 27 methylation in X inactivation. Science 300(5616), 131–135 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai MC, Manor O, Wan Y et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329(5992), 689–693 (2010).
   PubMed Web of Science ®Google Scholar
• Khalil AM, Guttman M, Huarte M et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106(28), 11667–11672 (2009).
   PubMed Web of Science ®Google Scholar
• Guttman M, Donaghey J, Carey BW et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477(7364), 295–300 (2011).
   PubMed Web of Science ®Google Scholar
• Kaneko S, Li G, Son J et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 24(23), 2615–2620 (2010).
   PubMed Web of Science ®Google Scholar
• Brill LM, Xiong W, Lee KB et al. Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5(2), 204–213 (2009).
   PubMed Web of Science ®Google Scholar
• Huttlin EL, Jedrychowski MP, Elias JE et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143(7), 1174–1189 (2010).
   PubMed Web of Science ®Google Scholar
• Chen S, Bohrer LR, Rai AN et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 12(11), 1108–1114 (2010).
   PubMed Web of Science ®Google Scholar
• Palacios D, Mozzetta C, Consalvi S et al. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7(4), 455–469 (2010).
   PubMed Web of Science ®Google Scholar
• Wei Y, Chen YH, Li LY et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13(1), 87–94 (2011).
   PubMed Web of Science ®Google Scholar
• Cha TL, Zhou BP, Xia W et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310(5746), 306–310 (2005).
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624–629 (2002).
   PubMed Web of Science ®Google Scholar
• Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24(2), 268–273 (2006).
   PubMed Web of Science ®Google Scholar
• Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J. Gastroenterol. Hepatol. 26(1), 19–27 (2011).
   Google Scholar
• Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695–1699 (2008).
   PubMed Web of Science ®Google Scholar
• Lu J, He ML, Wang L et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 71(1), 225–233 (2011).
   PubMed Web of Science ®Google Scholar
• Alajez NM, Shi W, Hui AB et al. Enhancer of zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 1, e85 (2010).
   PubMed Web of Science ®Google Scholar
• Kisliouk T, Yosefi S, Meiri N. miR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition. Eur. J. Neurosci. 33(2), 224–235 (2011).
   PubMed Web of Science ®Google Scholar
• Cheng AS, Lau SS, Chen Y et al. EZH2-mediated concordant repression of Wnt antagonists promotes b-catenin-dependent hepatocarcinogenesis. Cancer Res. 71(11), 4028–4039 (2011).
   PubMed Web of Science ®Google Scholar
• Jiang X, Tan J, Li J et al. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13(6), 529–541 (2008).
   PubMed Web of Science ®Google Scholar
• Hussain M, Rao M, Humphries AE et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 69(8), 3570–3578 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Li X, Toy K et al. Downregulation of EZH2 decreases growth of estrogen receptor invasive breast carcinoma and requires BRAC1. Oncogene 28(6), 843–853 (2009).
   PubMed Web of Science ®Google Scholar
• Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4α tumor suppressor gene. Genes Dev. 21(1), 49–54 (2007).
   PubMed Web of Science ®Google Scholar
• Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21(5), 525–530 (2007).
   PubMed Web of Science ®Google Scholar
• Min J, Zaslavsky A, Fedele G et al. An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nat. Med. 16(3), 286–294 (2010).
   PubMed Web of Science ®Google Scholar
• Song LB, Li J, Liao WT et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial–mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119(12), 3626–3636 (2009).
   PubMed Web of Science ®Google Scholar
• Yu J, Cao Q, Mehra R et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12(5), 419–431 (2007).
   PubMed Web of Science ®Google Scholar
• Schuringa JJ, Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr. Opin. Hematol. 17(4), 294–299 (2010).
   PubMed Web of Science ®Google Scholar
• Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the polycomb-group genes EED and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13(20), 2691–2703 (1999).
   PubMed Web of Science ®Google Scholar
• Majewski IJ, Ritchie ME, Phipson B et al. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood 116(5), 731–739 (2010).
   PubMed Web of Science ®Google Scholar
• Mochizuki-Kashio M, Mishima Y, Miyagi S et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 118(25), 6553–6561 (2011).
   PubMed Web of Science ®Google Scholar
• Grubach L, Juhl-Christensen C, Rethmeier A et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur. J. Haematol. 81(2), 112–122 (2008).
   PubMed Web of Science ®Google Scholar
• Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 115(15), 3098–3108 (2010).
   PubMed Web of Science ®Google Scholar
• Xu F, Li X, Wu L et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann. Hematol. 90(6), 643–653 (2010).
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364(26), 2496–2506 (2011).
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181–185 (2010).
   PubMed Web of Science ®Google Scholar
• Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107(49), 20980–20985 (2010).
   PubMed Web of Science ®Google Scholar
• Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117(8), 2451–2459 (2011).
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7(3), 299–313 (2010).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Glazer RI, Hartman KD, Knode MC et al. 3-deazaneplanocin: a new and potent inhibitor of S-adenosyl homocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 135(2), 688–694 (1986).
   PubMed Web of Science ®Google Scholar
• Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther. 8(12), 3191–3202 (2009).
   PubMed Web of Science ®Google Scholar
• Chiba T, Suzuki E, Negishi M et al. 3-deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int. J. Cancer doi:10.1002/ijc.26264 (2011) (Epub ahead of print).
   Google Scholar
• Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579–1588 (2009).
   PubMed Web of Science ®Google Scholar
• Hayden A, Johnson PW, Packham G, Crabb SJ. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res. Treat. 127(1), 109–119 (2011).
   PubMed Web of Science ®Google Scholar
• Hua WF, Fu YS, Liao YJ et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 637(1–3), 16–21 (2010).
   PubMed Web of Science ®Google Scholar
• Suv ML, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69(24), 9211–9218 (2009).
   PubMed Web of Science ®Google Scholar